Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Enterprise Value (2020 - 2025)

Insight Molecular Diagnostics' Enterprise Value history spans 6 years, with the latest figure at -$19.4 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 471.44% year-over-year to -$19.4 million; the TTM value through Sep 2025 reached -$19.4 million, down 471.44%, while the annual FY2024 figure was -$8.6 million, 8.44% up from the prior year.
  • Enterprise Value for Q3 2025 was -$19.4 million at Insight Molecular Diagnostics, up from -$24.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$400000.0 in Q3 2022 and bottomed at -$47.6 million in Q2 2021.
  • The 5-year median for Enterprise Value is -$14.4 million (2023), against an average of -$18.2 million.
  • The largest annual shift saw Enterprise Value surged 99.1% in 2022 before it crashed 773.21% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$33.9 million in 2021, then surged by 39.66% to -$20.4 million in 2022, then skyrocketed by 53.82% to -$9.4 million in 2023, then increased by 8.44% to -$8.6 million in 2024, then crashed by 124.98% to -$19.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Enterprise Value are -$19.4 million (Q3 2025), -$24.3 million (Q2 2025), and -$31.0 million (Q1 2025).